Elanco Animal Health Incorporated $ELAN Shares Sold by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP reduced its stake in Elanco Animal Health by 2.6%, selling over 103,000 shares, while still holding approximately 3.89 million shares valued at about $40.85 million.
• Several institutional investors have increased their positions in Elanco, with Dimensional Fund Advisors boosting its stake by 14.3% and owning over 20 million shares worth approximately $214.87 million.
• Analysts have raised their price targets for Elanco, with Piper Sandler increasing it from $12.00 to $18.00 and the stock currently has a consensus rating of "Moderate Buy" with an average price target of $17.33.

Wellington Management Group LLP trimmed its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 2.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,890,056 shares of the company's stock after selling 103,592 shares during the quarter. Wellington Management Group LLP owned about 0.78% of Elanco Animal Health worth $40,846,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Allworth Financial LP raised its stake in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after purchasing an additional 2,090 shares during the last quarter. CoreCap Advisors LLC purchased a new position in Elanco Animal Health during the fourth quarter valued at approximately $29,000. Parallel Advisors LLC raised its position in Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after acquiring an additional 1,852 shares in the last quarter. NBC Securities Inc. purchased a new position in Elanco Animal Health during the first quarter valued at approximately $40,000. Finally, Versant Capital Management Inc raised its position in Elanco Animal Health by 65.9% during the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after acquiring an additional 1,740 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN traded down $0.08 during trading on Friday, reaching $18.38. The stock had a trading volume of 71,268,743 shares, compared to its average volume of 7,713,274. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The business has a fifty day moving average price of $15.55 and a 200-day moving average price of $12.69. The stock has a market cap of $9.13 billion, a PE ratio of 21.37, a PEG ratio of 3.42 and a beta of 1.66. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $18.87.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business's revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ELAN. Piper Sandler lifted their price target on Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, August 11th. Stifel Nicolaus lifted their price target on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Finally, Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.